{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:44:06Z","timestamp":1778946246651,"version":"3.51.4"},"reference-count":32,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Astellas Pharma Inc., Ltd., Tokyo, Japan","award":["20160318"],"award-info":[{"award-number":["20160318"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Patients with quiescent inflammatory bowel disease (IBD) frequently suffer diarrhea-predominant irritable bowel syndrome (IBS-D)-like symptoms, such as abdominal pain or stool irregularities. Here, we assessed the effect of ramosetron, a serotonin type 3 (5-HT3) receptor antagonist, on IBS-D-like symptoms in patients with quiescent IBD. Seventy patients with quiescent IBD, who met the Rome III diagnostic criteria for IBS-D, were randomly assigned to receive either ramosetron (5 \u03bcg; n = 35) or a placebo (n = 35) orally once daily for 4 weeks. The primary endpoint was the responder rate for global assessment of relief from overall IBS-D-like symptoms. The responder rates for relief of abdominal pain\/discomfort and improvement of bowel habits were also evaluated. The responder rate for relief from overall IBS-D-like symptoms at the final evaluation point was significantly higher in the ramosetron group (35.5%) than in the placebo group (11.4%) (p = 0.037). The responder rate for improvement of bowel habits was significantly higher in the ramosetron group (38.7%) than in the placebo group (14.3%) (p = 0.028). The reduction of stool frequency was significantly greater in the ramosetron group than in the placebo group (p = 0.044). Ramosetron is effective for relief of overall IBS-D-like symptoms in patients with quiescent IBD.<\/jats:p>","DOI":"10.3390\/jcm11236882","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T08:29:58Z","timestamp":1669105798000},"page":"6882","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1283-9009","authenticated-orcid":false,"given":"Toshihiko","family":"Tomita","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Fukui","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Morishita","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumire","family":"Mori","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6949-932X","authenticated-orcid":false,"given":"Tadayuki","family":"Oshima","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-618X","authenticated-orcid":false,"given":"Shinichiro","family":"Shinzaki","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9844-642X","authenticated-orcid":false,"given":"Hiroto","family":"Miwa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4110\/in.2017.17.1.25","article-title":"Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies","volume":"17","author":"Kim","year":"2017","journal-title":"Immune Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0002-9270(01)04037-0","article-title":"Quality of life in inflammatory bowel disease in remission: The impact of IBS-like symptoms and associated psychological factors","volume":"97","author":"Axelsson","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"661","DOI":"10.5056\/jnm15160","article-title":"Prevalence of irritable bowel syndrome-like symptoms in Japanese patients with inactive inflammatory bowel disease","volume":"22","author":"Tomita","year":"2016","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/gutjnl-2012-304066","article-title":"Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation","volume":"63","author":"Bzioueche","year":"2014","journal-title":"Gut"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cgh.2016.05.012","article-title":"Negative effects on psychological health and quality of life of genuine irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease","volume":"15","author":"Gracie","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/ajg.2010.156","article-title":"Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: A real association or reflection of occult inflammation?","volume":"105","author":"Keohane","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cgh.2013.11.024","article-title":"Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea","volume":"12","author":"Fukudo","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/j.gastro.2015.10.047","article-title":"Ramosetron reduces symptoms of irritable bowel syndrome with Diarrhea and improves quality of life in women","volume":"150","author":"Fukudo","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2982.2011.01771.x","article-title":"Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: A multicenter, randomized clinical trial, compared with mebeverine","volume":"23","author":"Lee","year":"2011","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1080\/00365520802240255","article-title":"A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome","volume":"43","author":"Matsueda","year":"2008","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000150632","article-title":"A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome","volume":"77","author":"Matsueda","year":"2008","journal-title":"Digestion"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Yu, T., Tang, Y., Xiong, W., Shen, X., Jiang, L., and Lin, L. (2017). Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0172846"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Qi, Q., Zhang, Y., Chen, F., Zuo, X., and Li, Y. (2018). Ramosetron for the treatment of irritable bowel syndrome with diarrhea: A systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterol., 18.","DOI":"10.1186\/s12876-017-0734-2"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","article-title":"Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomized trial","volume":"298","author":"Rachmilewitz","year":"1989","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5056\/jnm15016","article-title":"Validity and reliability of the Japanese version of the Rome III diagnostic questionnaire for irritable bowel syndrome and functional dyspepsia","volume":"21","author":"Kanazawa","year":"2015","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_18","first-page":"55","article-title":"Efficacy of serotonin type 3 receptor antagonist ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome with inactive Crohn\u2019s disease, a pilot trial","volume":"26","author":"Nakamura","year":"2014","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/BF03013138","article-title":"Ramosetron vs. granisetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy","volume":"46","author":"Fujii","year":"1999","journal-title":"Can. J. Anaesth."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000098418","article-title":"Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study","volume":"53","author":"Shi","year":"2007","journal-title":"Chemotherapy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1634\/theoncologist.2015-0128","article-title":"Ramosetron versus Ondansetron in combination with aprepitant and dexamethasone for the prevention of highly Emetogenic chemotherapy-induced nausea and vomiting: A multicenter, randomized phase III trial, KCSG PC10-21","volume":"20","author":"Kim","year":"2015","journal-title":"Oncologist"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1254\/jjp.69.205","article-title":"Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents","volume":"69","author":"Miyata","year":"1995","journal-title":"Jpn. J. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1053\/j.gastro.2011.03.011","article-title":"The HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome","volume":"140","author":"Kilpatrick","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_24","first-page":"G827","article-title":"Involvement of the 5-HT3 receptor in CRH-induced defecation in rats","volume":"274","author":"Miyata","year":"1998","journal-title":"Am. J. Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"12384","DOI":"10.1038\/s41598-018-30943-3","article-title":"Effect of probiotic Bifidobacterium bifidum G9-1 on the relationship between gut microbiota profile and stress sensitivity in maternally separated rats","volume":"8","author":"Fukui","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/nrdp.2016.14","article-title":"Irritable bowel syndrome","volume":"2","author":"Enck","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0924-977X(99)00065-6","article-title":"5-HT(3) receptor antagonists and anxiety; a preclinical and clinical review","volume":"10","author":"Oliver","year":"2000","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1756284820971202","DOI":"10.1177\/1756284820971202","article-title":"Characterization of fungal and bacterial dysbiosis in young adult Chinese patients with Crohn\u2019s disease","volume":"13","author":"Qiu","year":"2020","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"16731","DOI":"10.1073\/pnas.0804812105","article-title":"Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients","volume":"105","author":"Sokol","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ibd.20330","article-title":"Active Crohn\u2019s disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora","volume":"14","author":"Swidsinski","year":"2008","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1086\/526774","article-title":"Postinfectious irritable bowel syndrome","volume":"46","author":"DuPont","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"13606","DOI":"10.1038\/s41598-017-12618-7","article-title":"Evidence for long-term sensitization of the bowel in patients with post-infectious-IBS","volume":"7","author":"Balemans","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/23\/6882\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:24:08Z","timestamp":1760145848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/23\/6882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":32,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["jcm11236882"],"URL":"https:\/\/doi.org\/10.3390\/jcm11236882","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]}}}